In 2021, Gamble et al. provided further insights into germline CDH1 variants but found no specific genotype that could predict whether patients would develop gastric or breast cancer, underscoring the need for individualized clinical management (Gamble et al. 2022). The gene discussed is CDH1; the disease is breast cancer.